Skip to main content
Beilstein Journal of Organic Chemistry logoLink to Beilstein Journal of Organic Chemistry
. 2006 Oct 31;2:21. doi: 10.1186/1860-5397-2-21

ADDP and PS-PPh3: an efficient Mitsunobu protocol for the preparation of pyridine ether PPAR agonists

Paul S Humphries 1,, Quyen-Quyen T Do 1, David M Wilhite 1
PMCID: PMC1705810  PMID: 17076898

Abstract

A series of pyridine ether PPAR agonists were synthesized through an ADDP and PS-PPh3 modified Mitsunobu protocol, which eliminated significant by-product formation. This method proved to be versatile, efficient and amenable to parallel synthesis.

Findings

Peroxisome proliferator-activated receptors (PPARs) are pharmaceutical targets of great importance. Their wide-ranging effects on key transcriptional pathways for lipid handling, insulin sensitivity, inflammation and other functions have led to marketed drugs and vast clinical and preclinical research efforts.[111]

In 1991, a series of PPAR analogues were disclosed, which for the first time did not contain a thiazolidine-2,4-dione pharmacophore.[12] These were propanoic acid derivatives with α-substitution to collectively serve as a mimic for the thiazolidine-2,4-dione ring. Based on the above and a knowledge of PPAR ligands publicly disclosed, we wished to synthesize compounds represented by the general structure 1 (Figure 1). Aromatic ethers are structural motifs found in many naturally occurring molecules and compounds of medicinal interest.[13] We envisaged the pyridyl ether moiety of 1 to be efficiently formed via Mitsunobu coupling of the requisite pyridinol and alkyl alcohols.[1417]

Figure 1.

Figure 1

Thiazolidine-2,4-dione mimic & chosen lead scaffold.

Our first attempt at the Mitsunobu reaction between pyridinol 2 and alcohol 3, utilizing a modification of the conditions originally reported by Mitsunobu,[18] afforded pyridyl ether 4 in 54% yield (Scheme 1). Interestingly, the reaction did not reach completion and pyridinol 2 was recovered, despite the fact that it was the limiting reagent. Upon closer examination, compound 5 was observed as a major by-product (46% based on 3).

Scheme 1.

Scheme 1

Reagents and conditions: (a) PS-PPh3, DEAD, THF, rt, 16 h, 54%.

By-products analogous to 5 have been observed in the literature when diethyl azodicarboxylate (DEAD) is used in certain Mitsunobu reactions.[1819] This by-product formation is believed to be dependent on the pKa of the acidic component (e.g. 2).[18] If the phenol has a pKa > 11, the yield is considerably lower; and with the phenol having pKa > 13, the desired reaction does not occur. The hydrazo anion 6, in these cases, attacks the alkoxyphosphonium directly to afford alkylated hydrazine derivative 7 as the by-product (side reaction in Figure 2),[19] since anion 6 is not efficient in deprotonating the weakly acidic phenol.

Figure 2.

Figure 2

Proposed mechanism of the Mitsunobu reaction.

One way to improve the above redox system is to enhance the basicity of anion 6 by the replacement of the alkoxy group OEt in DEAD with strong electron donating groups such as NR2.[16] Thus, 1,1'-(azodicarbonyl)dipiperidine (ADDP),[20] 4,7-dimethyl-3,5,7-hexahydro-1,2,4,7-tetrazocin-3,8-dione (DHTD),[21] and N,N,N',N'-tetramethylazodicarboxamide (TMAD)[22] have been developed as new reagents in combination with tributyl phosphine (TBP).

We initially chose ADDP, due to its commercial availability and low cost. The original reference utilized ADDP and TBP in benzene,[20] but due to safety and ease of handling we chose to keep PS-PPh3 and THF. Our first attempt was successful and no by-product 8 was observed in the reaction (Scheme 2) [see Supporting Information File 1 and Supporting Information File 2]. With the above result in hand, we then pursued a variety of targets by performing the modified Mitsunobu reaction of 2 and a variety of primary alcohols (Table 1). In general, a variety of diverse alcohols afforded the expected products in excellent yield. As expected, oxazoles, thiazoles, pyrazoles, and pyridines are tolerated in this chemistry. In a limited number of cases, functionality (e.g. basic amines, benzimidazoles, indoles, etc.) caused no reaction to occur and only recovered starting materials were isolated (data not shown).

Scheme 2.

Scheme 2

Reagents and conditions: (a) PS-PPh3, ADDP, THF, rt, 16 h, 81%.

Table 1.

Modified Mitsunobu coupling of pyridinol 2 and a variety of primary alcoholsa

graphic file with name Beilstein_J_Org_Chem-02-21-i016.jpg
Entry Alcohol Product Yield (%) Entry Alcohol Product Yield (%)

1 graphic file with name Beilstein_J_Org_Chem-02-21-i017.jpg 9 81 7 graphic file with name Beilstein_J_Org_Chem-02-21-i018.jpg 15 79
2 graphic file with name Beilstein_J_Org_Chem-02-21-i001.jpg 10 78 8 graphic file with name Beilstein_J_Org_Chem-02-21-i002.jpg 16 85
3 graphic file with name Beilstein_J_Org_Chem-02-21-i003.jpg 11 80 9 graphic file with name Beilstein_J_Org_Chem-02-21-i004.jpg 17 77
4 graphic file with name Beilstein_J_Org_Chem-02-21-i005.jpg 12 83 10 graphic file with name Beilstein_J_Org_Chem-02-21-i006.jpg 18 80
5 graphic file with name Beilstein_J_Org_Chem-02-21-i007.jpg 13 71 11 graphic file with name Beilstein_J_Org_Chem-02-21-i008.jpg 19 72
6 graphic file with name Beilstein_J_Org_Chem-02-21-i009.jpg 14 81 12 graphic file with name Beilstein_J_Org_Chem-02-21-i010.jpg 20 76

a Reactions were run using 0.5 mmol pyridinol, 0.55 mmol alcohol, 0.75 mmol PS-PPh3, 0.75 mmol ADDP and 5.5 mL tetrahydrofuran.

We then shifted our attention to variation of the pyridinol, whilst holding constant the 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethanol reactant 3 (Table 2). As expected, variation of the 2-substituent of the pyridine ring resulted in equally high yields.

Table 2.

Modified Mitsunobu coupling of alcohol 3 and a variety of pyridinolsa

graphic file with name Beilstein_J_Org_Chem-02-21-i011.jpg
Entry Pyridinol Product Yield (%) Entry Pyridinol Product Yield (%)

1 graphic file with name Beilstein_J_Org_Chem-02-21-i012.jpg 21 86 3 graphic file with name Beilstein_J_Org_Chem-02-21-i013.jpg 23 84
2 graphic file with name Beilstein_J_Org_Chem-02-21-i014.jpg 22 95 4 graphic file with name Beilstein_J_Org_Chem-02-21-i015.jpg 24 78

a Reactions were run using 0.5 mmol pyridinol, 0.55 mmol alcohol, 0.75 mmol PS-PPh3, 0.75 mmol ADDP and 5.5 mL tetrahydrofuran.

Having efficiently synthesized a diverse set of intermediate esters, we then sought an expedient method for obtaining the final carboxylic acids. We opted for a microwave-assisted procedure for this basic hydrolysis step. As shown in Scheme 3, the carboxylic acids (e.g. 25) could be obtained in a matter of minutes [see Supporting Information File 1 and Supporting Information File 2]. The significant reduction in reaction time resulted in a productivity enhancement due to increased sample processing. A number of the other esters described in this manuscript were also subjected to these conditions and all afforded the pure carboxylic acids in 82–100% yield.

Scheme 3.

Scheme 3

Reagents and conditions: (a) 1 N aq. NaOH, MeCN, 100°C μW, 10 mins, 96%.

In summary, we have developed a modified Mitsunobu protocol utilizing 1,1'-(azodicarbonyl)dipiperidine (ADDP) and polymer-supported triphenylphosphine (PS-PPh3). Employment of this method resulted in a rapid, convenient, and high-yielding two step protocol for the preparation of PPAR agonists. In particular, the modified Mitsunobu coupling of pyridinols and alcohols proved to be versatile, efficient and amenable to parallel synthesis. A full account of the medicinal chemistry of these compounds will be given elsewhere.

Supporting Information

File 1

Supporting Information. Experimental procedures and data for all novel compounds described in this manuscript.

File 2

Auxiliary Data. Auxiliary data for all novel compounds described in this manuscript.

Acknowledgments

The authors would like to thank John Tatlock and Simon Bailey for stimulating discussions and feedback on this manuscript.

Contributor Information

Paul S Humphries, Email: paul.humphries@pfizer.com.

Quyen-Quyen T Do, Email: quyen-quyen.do@pfizer.com.

David M Wilhite, Email: david.wilhite@pfizer.com.

References

  • 1.Ram V J. Drugs Today. 2003;39:609–632. doi: 10.1358/dot.2003.39.8.799408. [DOI] [PubMed] [Google Scholar]
  • 2.Sternbach D D. Annu Rep Med Chem. 2003;38:71–80. [Google Scholar]
  • 3.Miller A R, Etgen G J. Expert Opin Invest Drugs. 2003;12:1489–1500. doi: 10.1517/13543784.12.9.1489. [DOI] [PubMed] [Google Scholar]
  • 4.Willson T M, Brown P J, Sternbach D D, Henke B R. J Med Chem. 2000;43:527–550. doi: 10.1021/jm990554g. [DOI] [PubMed] [Google Scholar]
  • 5.van Raalte D H, Li M, Pritchard P H, Wasan K M. Pharm Res. 2004;21:1531–1538. doi: 10.1023/B:PHAM.0000041444.06122.8d. [DOI] [PubMed] [Google Scholar]
  • 6.Miyachi H. Expert Opin Ther Pat. 2004;14:607–618. [Google Scholar]
  • 7.Henke B R. Prog Med Chem. 2004;42:1–53. doi: 10.1016/S0079-6468(04)42001-3. [DOI] [PubMed] [Google Scholar]
  • 8.Fajas L, Auwerx J. Peroxisome proliferator-activated receptor γ and the transcriptional control of adipogenesis and metabolism. In: Bray G A, Bouchard C, editors. Handbook of Obesity: Etiology and Pathophysiology. New York: Marcel Dekker; 2004. pp. 559–587. [Google Scholar]
  • 9.Evans R M, Barish G D, Wang Y-X. Nat Med. 2004;10:355–361. doi: 10.1038/nm1025. [DOI] [PubMed] [Google Scholar]
  • 10.Pershadsingh H A. Expert Opin Invest Drugs. 2004;13:215–228. doi: 10.1517/13543784.13.3.215. [DOI] [PubMed] [Google Scholar]
  • 11.Tan N S, Michalik L, Desvergne B, Wahli W. Expert Opin Ther Targets. 2004;8:39–48. doi: 10.1517/14728222.8.1.39. [DOI] [PubMed] [Google Scholar]
  • 12.Hulin B, inventor. 3-Aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents. WO 91/19702 A1. PCT Int. Appl. 1991 Dec 26; Chem. Abstr.,1992,117, 26552r.
  • 13.Czarnik A W. Acc Chem Res. 1996;29:112–113. doi: 10.1021/ar950256n. [DOI] [PubMed] [Google Scholar]
  • 14.Mitsunobu O. Synthesis. 1981:1–28. doi: 10.1055/s-1981-29317. [DOI] [Google Scholar]
  • 15.Hughes D L. Org React. 1992;42:335–656. [Google Scholar]
  • 16.Ito S, Tsunoda T. Pure Appl Chem. 1999;71:1053–1057. doi: 10.1351/pac199971061053. A brief review. [DOI] [Google Scholar]
  • 17.Valentine D H, Hillhouse J H. Synthesis. 2003:317–334. [Google Scholar]
  • 18.Wada M, Mitsunobu O. Tetrahedron Lett. 1972;13:1279–1282. doi: 10.1016/S0040-4039(01)84567-6. [DOI] [Google Scholar]
  • 19.von Itzstein M, Jenkins I D. J Chem Soc, Perkin Trans 1. 1986:437–445. doi: 10.1039/p19860000437. [DOI] [Google Scholar]
  • 20.Tsunoda T, Yamamiya Y, Ito S. Tetrahedron Lett. 1993;34:1639–1642. doi: 10.1016/0040-4039(93)85029-V. [DOI] [Google Scholar]
  • 21.Tsunoda T, Kawamura Y, Uemoto K, Ito S. Heterocycles. 1998;47:177–179. [Google Scholar]
  • 22.Tsunoda T, Otsuka J, Yamamiya Y, Ito S. Chem Lett. 1994:539–542. doi: 10.1246/cl.1994.539. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

File 1

Supporting Information. Experimental procedures and data for all novel compounds described in this manuscript.

File 2

Auxiliary Data. Auxiliary data for all novel compounds described in this manuscript.


Articles from Beilstein Journal of Organic Chemistry are provided here courtesy of Beilstein-Institut

RESOURCES